A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 498 participants.
Also called NCT03687827
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 498 participants
- Sponsor
- Registry
-
NCT03687827 -
2017-004047-20
-
- Other papers using this trial's data
- Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Poland, Puerto Rico, Slovakia, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT03687827. Randomized; no masking; primary purpose treatment. Start 2018-10-02 (actual); primary completion 2019-12-20 (actual). Results posted on 2021-01-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
- Acronym
- SWITCH PRO
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin degludec
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03687827- Content hash
3c61521568343ae661e826f35c013668175574f7d2e0c49366333ae45de6644e